

Holger Gothe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384313/publications.pdf>

Version: 2024-02-01

48
papers

2,276
citations

394421

19
h-index

223800

46
g-index

70
all docs

70
docs citations

70
times ranked

2788
citing authors

#	ARTICLE	IF	CITATIONS
1	Is there an unmet medical need for palliative care services in Germany? Incidence, prevalence, and 1-year all-cause mortality of palliative care sensitive conditions: real-world evidence based on German claims data. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 711-720.	1.6	7
2	Epidemiology and routine care treatment of patients with hip or knee osteoarthritis and chronic lower back pain: real-world evidence from Germany. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, 30, 2855-2867.	1.6	3
3	Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: A survey among physicians. <i>Preventive Medicine Reports</i> , 2022, 28, 101861.	1.8	1
4	Jetzt einmalige Chance für Covid-19-Forschung nutzen. <i>Monitor Versorgungsforschung</i> , 2021, 14, 28-30.	0.0	0
5	A Germany-wide survey study on the patient journey of patients with hereditary angioedema. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 221.	2.7	9
6	Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data. <i>PLoS ONE</i> , 2020, 15, e0231846.	2.5	16
7	The patient journey of patients with Fabry disease, Gaucher disease and Mucopolysaccharidosis type II: A German-wide telephone survey. <i>PLoS ONE</i> , 2020, 15, e0244279.	2.5	8
8	Economic burden of stroke: a systematic review on post-stroke care. <i>European Journal of Health Economics</i> , 2019, 20, 107-134.	2.8	300
9	Algorithms to identify COPD in health systems with and without access to ICD coding: a systematic review. <i>BMC Health Services Research</i> , 2019, 19, 737.	2.2	26
10	Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. <i>BMC Neurology</i> , 2019, 19, 318.	1.8	24
11	PMU9 - PALLIATIVE CARE IN GERMANY: AN EPIDEMIOLOGICAL STUDY BASED ON REAL WORLD DATA. <i>Value in Health</i> , 2018, 21, S309-S310.	0.3	0
12	Assessing Type and Impact of Biases Potentially Occurring when Analyzing Real World Evidence: The Case of Second Line Treatment for Ovarian Cancer. <i>Value in Health</i> , 2018, 21, S213.	0.3	0
13	Comparative Effectiveness Analysis Using Real World Evidence (RWE) and Applying a Causal Marginal Structural Model: the Case of Second-Line Treatment in Patients with Ovarian Cancer. <i>Value in Health</i> , 2018, 21, S18.	0.3	0
14	Do patients with lactose intolerance exhibit more frequent comorbidities than patients without lactose intolerance? An analysis of routine data from German medical practices. <i>Annals of Gastroenterology</i> , 2016, 29, 174-9.	0.6	18
15	The Use Of Administrative Data To Determine Prevalence And Incidence Of Copd: A Systematic Review. <i>Value in Health</i> , 2016, 19, A368-A369.	0.3	2
16	Economic Burden of Stroke: A Systematic Review on Post-Stroke Care. <i>Value in Health</i> , 2016, 19, A633.	0.3	8
17	Standardisierte BerichtsRoutine für Sekundärdaten Analysen (STROSA) – ein konsentierter Berichtsstandard für Deutschland, Version 2. <i>Gesundheitswesen</i> , 2016, 78, e145-e160.	0.5	95
18	The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 21-33.	2.1	25

#	ARTICLE	IF	CITATIONS
19	Health technology assessment of utilization, practice and ethical issues of self-pay services in the German ambulatory health care setting. <i>International Journal of Public Health</i> , 2014, 59, 175-187.	2.3	1
20	The Impact of Generic Substitution on Health Outcomes and Costs: A Systematic Review. <i>Value in Health</i> , 2013, 16, A458.	0.3	1
21	The Epidemiology of Osteoporosis. <i>Deutsches A&#x0308;rzteblatt International</i> , 2013, 110, 52-7.	0.9	178
22	The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2013, 51, 868-872.	0.6	28
23	PHP153 Supporting Payers with Collaborative HTA Tools in Making Evidence-Based Decisions: The United States Experience and International Needs in Europe and Globally. <i>Value in Health</i> , 2012, 15, A316.	0.3	0
24	Individual health services. <i>GMS Health Technology Assessment</i> , 2011, 7, Doc05.	2.2	3
25	Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. <i>The Cochrane Library</i> , 2010, , CD006632.	2.8	451
26	Excess Health Care Costs of Obesity in Adults with Diabetes Mellitus: a Claims Data Analysis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 496-504.	1.2	17
27	The experience of conducting a Cochrane systematic review of the impact of clinical pathways on professional practice, patient outcomes, length of stay and hospital costs. <i>International Journal of Care Pathways</i> , 2009, 13, 62-66.	0.5	2
28	PMH2 EVIDENCE FOR SSRI IN THE TREATMENT OF DEPRESSION: EARLY KNOWLEDGE GAIN“LATE CONSEQUENCES IN ROUTINE CARE?. <i>Value in Health</i> , 2009, 12, A350.	0.3	0
29	Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. <i>Patient Preference and Adherence</i> , 2009, 3, 25-30.	1.8	29
30	A systematic review and meta-analysis of the effects of clinical pathways on length of stay, hospital costs and patient outcomes. <i>BMC Health Services Research</i> , 2008, 8, 265.	2.2	121
31	PHP3 INNOVATIVE HEALTHTECHNOLOGIES IN THE “ANTI-AGING-MEDICINE“-FIELD: RESULTS FROM A SYSTEMATIC HORIZON SCANNING. <i>Value in Health</i> , 2008, 11, A363.	0.3	0
32	PMS67 HEALTH GAINS FOREGONE DUE TO THE SUSTAINED DELAY OF ADEQUATE UTILIZATION OF EVIDENCE BASED TREATMENTS: THE CASE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS. <i>Value in Health</i> , 2008, 11, A558.	0.3	0
33	PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION“A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND. <i>Value in Health</i> , 2008, 11, A597.	0.3	0
34	Persistence and adherence with antihypertensive drug therapy in a German sickness fund population. <i>Journal of Human Hypertension</i> , 2007, 21, 744-746.	2.2	26
35	Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 854-858.	1.9	19
36	The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2007, 16, 1167-1176.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Epidemiology, treatment and costs of osteoporosis in Germany—the BoneEVA Study. <i>Osteoporosis International</i> , 2007, 18, 77-84.	3.1	272
38	PMH31 PREDICTORS FOR REHOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA. <i>Value in Health</i> , 2006, 9, A319.	0.3	1
39	POB4 USING CLAIMS DATA TO UNDERSTAND THE COSTS OF DIFFERENT HEALTH STATES FOR PATIENTS WITH CARDIOMETABOLIC RISK. <i>Value in Health</i> , 2006, 9, A325.	0.3	1
40	Low persistency with oral bisphosphonates in cancer patients. <i>European Journal of Oncology Nursing</i> , 2006, 10, 220-221.	2.1	0
41	PRS2 PRESCRIPTION PATTERNS IN COPD PATIENTS IN A GERMAN SICKNESS FUND POPULATION. <i>Value in Health</i> , 2005, 8, A212.	0.3	0
42	Pathways to care and psychological problems of general practice patients in a 'gate keeper' and an 'open access' health care system. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2003, 38, 690-697.	3.1	47
43	PMD30 MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA. <i>Value in Health</i> , 2003, 6, 802.	0.3	1
44	Early Termination of Antidepressant Drug Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 523-530.	1.4	45
45	Specialty Training and the Personal Use of Benzodiazepines by Physicians Affect their Proneness to Prescribe Tranquilizers. <i>Pharmacopsychiatry</i> , 1998, 31, 42-47.	3.3	12
46	What Happens to Patients After the End of a Clinical Trial?. <i>Pharmacopsychiatry</i> , 1997, 30, 35-43.	3.3	3
47	Benzodiazepine Substitution in Medical Practice. <i>Pharmacopsychiatry</i> , 1993, 26, 107-113.	3.3	31
48	Benzodiazepines in Medical Teaching. <i>Pharmacopsychiatry</i> , 1993, 26, 6-10.	3.3	1